(p. 7A) A Henry Ford Health System study shows the malaria drug hydroxychloroquine helps lower the death rate of COVID-19 patients, the Detroit-based health system said Thursday [July 2, 2020].
The study analyzed 2,541 patients hospitalized among the system’s six hospitals and found 13% of those treated with hydroxychloroquine died while 26% of those who did not receive the drug died.
. . .
The new study, published in the International Society of Infectious Disease, found patients did not suffer heart-related side effects.
For the full story, see:
AP and Detroit News. “Coronavirus Developments.” Omaha World-Herald (Friday, July 3, 2020): 7A.
(Note: ellipsis, and bracketed date, added.)
The published version of the research summarized above, is:
Arshad, Samia; Paul Kilgore, Zohra S. Chaudhry, Gordon Jacobsen, Dee Dee Wang, Kylie Huitsing, Indira Brar, George J. Alangaden, Mayur S. Ramesh, John E. McKinnon, William O’Neill, Marcus Zervos, and Henry Ford COVID-19 Task Force. “Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with Covid-19.” International Journal for Infectious Diseases (published online in advance of print on July 1, 2020).